|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00460 SIHUAN PHARM
Nominal 
0.780 -0.040 (-4.878%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,161,218 | 1.310% | 2,618,008 | 1,901,109 | 1,860,539 | 2,181,189 |
| Cost of Sales | (479,561) | 23.297% | (816,150) | (659,399) | (564,895) | (693,608) |
| Gross Profit | 681,657 | -9.983% | 1,801,858 | 1,241,710 | 1,295,644 | 1,487,581 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (64,231) | -- | -- | -- | -- | (1,727,119) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 121,841 | -- | 11,607 | (15,226) | (53,621) | (80,875) | |
| Profit / (Loss) before Taxation | 365,984 | 133.224% | 417,156 | (428,288) | (161,260) | (2,122,778) | |
| Taxation | (153,405) | 69.079% | (231,752) | (43,261) | (96,427) | (196,794) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | 36,296 | |
| Non-controlling Interests | 12,125 | -66.698% | (5,708) | 254,887 | 203,670 | 368,358 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 224,704 | 119.003% | 179,696 | (216,662) | (54,017) | (1,914,918) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 47,271 | -14.636% | 102,748 | 99,383 | 121,429 | 64,382 |
| Depreciation & Amortisation | -- | -- | 62,432 | 84,995 | 79,735 | 99,150 |
| Directors' Emoluments | -- | -- | 16,375 | 17,141 | 18,497 | 17,937 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 2.490 | 124.324% | 1.970 | -2.340 | -0.580 | -20.520 |
| DPS (cts) | 0.000 | -- | 1.950 | 1.900 | 0.000 | 6.500 |
| Dividend Payout Ratio (%) | -- | -- | 98.985% | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.003) | 0.026 | 0.021 | 0.005 |
| NBV per share ($) | 0.674 | -- | 0.640 | 0.470 | 0.475 | 0.508 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 224,704 |
| %Change | 119.003% |
| EPS / (LPS) | RMB 0.025 |
| NBV Per Share (¥) | RMB 0.674 |